BARI-STEP:A Double-blinded, Randomised, Placebo-controlled Trial of Semaglutide 2.4 mg in Patients With Poor Weight-loss Following Bariatric Surgery.
Latest Information Update: 10 Nov 2023
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms BARI-STEP
- 06 Nov 2023 Planned End Date changed from 1 May 2024 to 1 Sep 2025.
- 06 Nov 2023 Planned primary completion date changed from 1 Mar 2024 to 1 Sep 2025.
- 06 Nov 2023 Status changed from recruiting to active, no longer recruiting.